To further investigate the effect of ALK signaling on SLC3A2 protein stability, cycloheximide (CHX) chase assays were performed in the presence or absence of lorlatinib in NB cell lines harboring ALK activating mutations. The gene discussed is SLC3A2; the disease is neuroblastoma.